New Discoveries in Dementia Research: The Results of Cumulus Neuroscience’s AAIC 2023 Presentation

At the Alzheimer’s Association International Conference 2023 in Amsterdam, Cumulus Neuroscience (Cumulus; The Company) unveiled interim findings from their real-world feasibility study CNS-101 which demonstrated the potential of their Neuroassessment Platform to revolutionise neuroscientific clinical trials and patient care.

Conducted in collaboration with the University of Cambridge and Trinity Biomedical Science Institute, this state-of-the-art platform empowers people to complete their assessments at home, using repeated sampling to generate meaningful, personalised data and insights.

Cumulus presented a compelling poster titled, “Feasibility of real-world endpoints of functional neurophysiology in Alzheimer’s disease dementia,” demonstrating that objective measures, such as EEG, are not only user-friendly for repeated at-home use by patients and older controls but are also yielding promising results.

Patients living with Alzheimer’s dementia (AD) showed remarkably high compliance rates (75%), while healthy controls recorded even better compliance (83.3%) during the initial 2-week burst stage.

Despite this intensive at-home sampling schedule, drop-out rates among participants remain low (AD patients, 20%; healthy controls, 6%). Initial analyses of EEG-based measures reliably aligned with traditional clinical benchmarks, indicating the effective validity and technical feasibility of this study.

Cumulus Founder and Chief Scientific Officer, Brian Murphy, PhD, has provided confirmation that people living with Alzheimer’s can effectively take part in clinical studies using at-home EEG. With high compliance rate and low dropout rate, our platform proved to bridge the gap between clinic-based biomarkers and purely digital markers providing accurate, accessible, and scalable tracking for large real-world studies and research. We are incredibly thankful to our research participants and collaborators for making this possible.

Alzheimer’s Disease (AD) is a devastating condition that is taking a toll on an unprecedented number of people around the world. It gradually affects brain function and memory, leading to a decline in cognitive abilities. While its precise causes are still unknown, it is the leading cause of dementia worldwide.

As the condition progresses, individuals may experience increasingly severe symptoms, such as memory loss, difficulty communicating, mood swings, and changes in behavior and personality. Sadly, at present, there is no known cure for this insidious disorder.

Researchers from the Boston University Chobanian & Avedisian School of Medicine presented a second poster at a recent conference displaying data gathered with the help of the Cumulus Neuroassessment Platform.

The study titled, “Implementing wearable technologies for in home assessment of cognitive and event-related potential responses after sleep and wakefulness in Alzheimer disease” aimed to determine the feasibility of usingwearable technologies to collect critical clinical study data directly from patient’s homes.

Results of the study were promising, with patients displaying high levels of adherence to the study protocol and demonstratinga strong willingness to participate in this new form of data collection.

This pioneering study confirms that collecting data at home using wearables has the potential to revolutionize how we monitor, detect, and assess brain function over long periods of time. We were delighted to see that patients were highly dedicated to the study protocol, and even more thrilled to discover that the data collected remotely was of the same quality as data normally collected at Boston University.

59 patients suffering from mild Alzheimer’s Disease and 60 healthy participants took part in the CNS-101 Study, a 1-year operational research project in the UK. The study aimed to evaluate and understand the impact of cognitive deterioration on brain activity and behavior.

Participants completed 15 home-based sessions of approximately 30 minutes each, consisting of a variety of behavioral tasks such as memory drills, executive functioning tasks, affective processing, and language tests.

Each participant also had EEG brainwave recordings taken using a cumulative 16-lead EEG headset during their 2-week burst stage. This exciting research is helping to build a comprehensive understanding of the decline of cognitive capabilities in Alzheimer’s Disease.

Cumulus is revolutionizing CNS clinical trials by enabling industry partners to monitor patients remotely across a spectrum of neurological domains. Through its cutting-edge precision, Cumulus allows for more accurate data collection and insight into the effects of treatment.

Dr. Budson and his team are supported by the generous contributions of Bristol Myers Squibb and Cumulus Neuroscience, enabling them to continue their groundbreaking work in advancing the understanding of neurological diseases and disabilities.

About Cumulus Neuroscience

At Cumulus Neuroscience, we are on a mission to revolutionize the diagnosis and treatment of Central Nervous System (CNS) disorders with an innovative AI-based, multi-domain digital biomarker platform.

Enabling key decision-making in medical research and clinical care, our platform will lead to faster, improved outcomes for millions of patients and caregivers across the world. Already powering the development of new therapies for Alzheimer’s Disease, depression and schizophrenia, 10 of the world’s foremost pharmaceutical companies are utilizing our platform’s potential for decentralized trials. Join us as we make a real difference in the medical field.

Discover the power of Cumulus, an industry-leading platform combining patented technology, experienced in-house expertise, and tailored industry partnerships. With its EEG headset seamlessly synced to its unique tablet-based neuro-assessment platform, Cumulus collects vast amounts of real-world, clinical data gathered over time from multiple behavioral and physiological domains in the patient’s home.

Supplemented by powerful machine learning analytics and the world’s largest database of annotated, longitudinal, neurofunctional data, Cumulus can drastically improve the accuracy and cost-efficiency of neuroscience clinical trials – providing valuable insights into the effectiveness of CNS treatments.

The Company boasts a world-class Scientific and Technical Advisory Board, and has the full support of highly experienced specialized investors, such as DDF/SV Health Investors, LifeArc and Future Fund. Together, this diverse team is dedicated to elevating the Company to new heights.

Leave a Comment